Introduction: Cerebrospinal fluid (CSF) biomarker quantification provides physicians with a reliable diagnosis of Alzheimer’s disease (AD). However, the relationship between their concentration and disease course has not been clearly elucidated. This work aimed to investigate the clinical and prognostic significance of Aβ40 CSF levels. Methods: A retrospective cohort of 76 patients diagnosed with AD using a decreased Aβ42/Aβ40 ratio was subclassified into hyposecretors (Aβ40 <7,755 pg/mL), normosecretors (Aβ40 7,755–16,715 pg/mL), and hypersecretors (Aβ40 >16,715 pg/mL). Potential differences in AD phenotype, Montreal Cognitive Assessment (MoCA) scores, and Global Deterioration Scale (GDS) stages were assessed. Correlation tests for biomarker concentrations were also performed. Results: Participants were classified as hyposecretors (n = 22, median Aβ40 5,870.500 pg/mL, interquartile range [IQR] 1,431), normosecretors (n = 47, median Aβ40 10,817 pg/mL, IQR 3,622), and hypersecretors (n = 7, 19,767 pg/mL, IQR 3,088). The distribution of positive phosphorylated Tau (p-Tau) varied significantly between subgroups and was more common in the normo- and hypersecretor categories (p = 0.003). Aβ40 and p-Tau concentrations correlated positively (ρ = 0.605, p < 0.001). No significant differences were found among subgroups regarding age, initial MoCA score, initial GDS stage, progression to the dementia stage, or changes in the MoCA score. Conclusion: In this study, we found no significant differences in clinical symptoms or disease progression in AD patients according to their CSF Aβ40 concentration. Aβ40 was positively correlated with p-Tau and total Tau concentrations, supporting their potential interaction in AD pathophysiology.

Alzheimer’s disease (AD) is the most frequent cause of dementia, affecting around 50 million people worldwide, with a prevalence expected to triplicate by 2050 [1]. Even though the mechanism underlying AD is still poorly understood, the “amyloid cascade” continues to be the most widely accepted hypothesis. Thus, the amyloid precursor protein is sequentially cleaved in the amyloidogenic pathway to amyloid-β peptides of various lengths. The longest ones, Aβ42 and Aβ40, are prone to aggregation in hypothetical conditions of overproduction or reduced clearance [2, 3]. The quantification of these peptides in cerebrospinal fluid (CSF) is nowadays an essential tool as they are reliable biomarkers for AD, even providing the basis for the definition of the disease itself, according to the latest diagnostic criteria [4]. Decreased Aβ42 in CSF has been previously correlated with higher amyloid deposits in pathological [5] and in vivo studies [6, 7], even predicting the progression to dementia from asymptomatic or mild cognitive impairment stages [8, 9]. However, no correlation has been found between CSF concentration of Aβ42 and cognitive symptoms [6, 8‒11]. Less is known about Aβ40, apart from that a decreased CSF Aβ42/Aβ40 ratio is a better indicator of amyloid deposits than Aβ42 alone [12‒14]. Therefore, the role of Aβ40 has been limited to adjusting for the interindividual variability in the total production of amyloid-β peptides [14]. With the present study, we aimed to evaluate the clinical and prognostic significance of the CSF levels of Aβ40.

Population of Study

We retrospectively analyzed the electronic clinical records of the patients with suspected cognitive impairment evaluated at Hospital Universitario La Paz, Madrid, Spain, from April 2019 to May 2022. The inclusion criteria were (1) diagnosis of the AD continuum by the CSF biomarker profile according to the National Institute of Ageing-Alzheimer’s Association (NIA-AA) research framework [4]; (2) age above 18 years old; (3) a neuroimaging study showing no signs suggestive of a non-neurodegenerative etiology; (4) laboratory tests with folate and B12 within normal range, normal thyroid, renal, and hepatic function; (5) negative syphilis and VIH serologies; and (6) at least one evaluation at the Cognitive Disorders Clinic. Patients with a progression to the dementia stage according to the Global Deterioration Scale (GDS) [15] in less than 6 months after the beginning of the symptoms were excluded, as well as those presenting signs in either the neuroimaging study or laboratory tests indicative of a non-neurodegenerative etiology. The study was approved by the Ethics Committee at Hospital Universitario La Paz on April 28th, 2022 (PI-5239). All data were managed in fulfillment of the Declaration of Helsinki.

Clinical and Neuropsychological Assessment

Every participant underwent a complete neurological examination on the first visit and a neuropsychological assessment with the Montreal Cognitive Assessment (MoCA) [16] or the Mini-Mental Status Examination (MMSE) [17] tests on the first visit and every 6 months while the follow-up lasted. Neurology consultants specialized in cognitive disorders performed neurological examinations and neuropsychological tests.

Biochemical Analysis

CSF samples were obtained by lumbar puncture and centrifuged for 10 min at 2,000 g and 20°C. The concentration of Aβ40, Aβ42, phosphorylated Tau (p-Tau), and total Tau were measured by chemiluminescence enzyme immunoassay on Lumipulse (Fujirebio®). A diagnosis of the AD continuum was established if the Aβ42/Aβ40 ratio <0.068 pg/mL. The threshold for p-Tau positivity was 59 pg/mL. Participants were classified according to the concentration of Aβ40 as follows: hyposecretors (Aβ40 <7,755 pg/mL), normosecretors (Aβ40 7,755–16,715 pg/mL), or hypersecretors (Aβ40 >16,715 pg/mL). The threshold values correspond to those provided by the manufacturer for diagnostic purposes [18, 19].

Variables of Study

Demographic data including sex, age, history of hypertension, diabetes mellitus, and dyslipidemia, as well as a family history of dementia, were collected. To assess the presentation and progression of cognitive symptoms in the participants, we recorded the initial symptoms and estimated time of onset as perceived by the patient or caregivers, the clinical phenotype according to the International Working Group criteria [20], the score on MoCA test, and GDS stage in the first consultation and during the follow-up. Seven patients underwent MMSE at some point during the follow-up, so the results were translated to MoCA scores using conversion tables [21].

Statistical Analysis

First, a raw analysis of the three subgroups established according to Aβ40 levels was performed. We also completed a stratified analysis based on p-Tau levels. Differences in qualitative variables were assessed with the χ2 test, and Fisher’s exact test was applied when a value was inferior to five. The Kolmogorov-Smirnov test was used to determine if the quantitative variables were normally distributed. Differences in quantitative values were assessed with Student’s t test or ANOVA when parametric analyses were deemed and with Mann-Whitney’s U test or Kruskal-Wallis’ test for nonparametric analyses. A Kaplan-Meier estimator was used to ascertain differences between groups in the progression to mild and moderate dementia stages (GDS ≥4 and GDS ≥5, respectively) [15], and changes in the MoCA score during the follow-up were standardized by dividing the difference by the interval between tests. Correlation among CSF biomarkers and the aforementioned clinical variables were assessed with Pearson’s and Spearman’s coefficients for normally and non-normally distributed variables, respectively. A logistic regression analysis was also performed to test the influence of CSF biomarkers on the phenotypical variants and progression of AD. SPSS 28 (IBM, Armonk, NY, USA) was used for the statistical analysis.

The inclusion criteria were met by 76 subjects, with a mean follow-up of 1.79 years (standard deviation [SD] = 1.01). The flowchart for patient selection is depicted in Figure 1. Of the 76 participants, 22 were classified as hyposecretors, 47 as normosecretors, and 7 as hypersecretors. Table 1 presents the concentration of CSF biomarkers for each subgroup. The demographic and clinical data for both raw and stratified analyses are shown in Table 2. No significant differences were found among groups regarding age, initial MoCA score, or initial GDS stage. The distribution of positive p-Tau status varied significantly across the subgroups, being more frequent in the normo- and hypersecretor categories (p = 0.003). No differences in demographic or clinical variables were found in the stratified analysis either. A positive correlation was found between Aβ40 and p-Tau levels (ρ = 0.605, p < 0.001), Aβ40, and total-Tau (ρ = 0.594, p < 0.001) and between Aβ40 and Aβ42 (ρ = 0.742, p < 0.001).

Fig. 1.

Flowchart for patient selection.

Fig. 1.

Flowchart for patient selection.

Close modal
Table 1.

Subgroup classification according to biomarker status

Hyposecretors, n = 22Normosecretors, n = 47Hypersecretors, n = 7p valueHyposecretorsNormosecretorsHypersecretorsp value
A+T+n = 11A+T−n = 11A+T+n = 42A+T−n = 5A+T+n = 6A+T−n = 1
40, median (IQR), pg/mL 5,870.500 (1,431) 10,817 (3,622) 19,767 (3,088) <0.001* 6,094 (1,512) 5,831 (2,115) 10,834.500 (3,967) 10,135 (4,296) 18,768 (2,868) 40,105 (0) <0.001* 
42, median (IQR), pg/mL 249.500 (101) 459 (242) 588 (185) <0.001* 268 (63) 241 (123) 435 (200) 654 (221) 597 (248) 228 (0) <0.001* 
42/Aβ40, mean (SD) 0.048 (0.01) 0.042 (0.01) 0.039 (0.01) 0.041* 0.044 (0.01) 0.053 (0.01) 0.040 (0.01) 0.061 (0.00) 0.036 (0.01) 0.056 <0.001* 
p-Tau, mean (SD), pg/mL 67.414 (34.44) 122.974 (66.48) 140.529 (67.61) <0.001* 93.146 (28.55) 41.681 (14.79) 131.017 (63.83) 38.525 (14.09) 158,883 (51.52) 30.400 <0.001* 
Total-Tau, mean (SD), pg/mL 448.270 (226.89) 744.790 (361.32) 944 (391.68) <0.001* 579.180 (189–02) 317.360 (186.21) 789.050 (345.15) 373 (294.94) 1,056.500 (278.90) 269 <0.001* 
Hyposecretors, n = 22Normosecretors, n = 47Hypersecretors, n = 7p valueHyposecretorsNormosecretorsHypersecretorsp value
A+T+n = 11A+T−n = 11A+T+n = 42A+T−n = 5A+T+n = 6A+T−n = 1
40, median (IQR), pg/mL 5,870.500 (1,431) 10,817 (3,622) 19,767 (3,088) <0.001* 6,094 (1,512) 5,831 (2,115) 10,834.500 (3,967) 10,135 (4,296) 18,768 (2,868) 40,105 (0) <0.001* 
42, median (IQR), pg/mL 249.500 (101) 459 (242) 588 (185) <0.001* 268 (63) 241 (123) 435 (200) 654 (221) 597 (248) 228 (0) <0.001* 
42/Aβ40, mean (SD) 0.048 (0.01) 0.042 (0.01) 0.039 (0.01) 0.041* 0.044 (0.01) 0.053 (0.01) 0.040 (0.01) 0.061 (0.00) 0.036 (0.01) 0.056 <0.001* 
p-Tau, mean (SD), pg/mL 67.414 (34.44) 122.974 (66.48) 140.529 (67.61) <0.001* 93.146 (28.55) 41.681 (14.79) 131.017 (63.83) 38.525 (14.09) 158,883 (51.52) 30.400 <0.001* 
Total-Tau, mean (SD), pg/mL 448.270 (226.89) 744.790 (361.32) 944 (391.68) <0.001* 579.180 (189–02) 317.360 (186.21) 789.050 (345.15) 373 (294.94) 1,056.500 (278.90) 269 <0.001* 

The largest subgroup corresponds to those patients with a concentration of CSF Aβ40 within the normal range. The values showed significant differences for every biomarker among subgroups.

IQR, interquartile range; n, number; p-Tau, phosphorylated Tau; q, quartile; SD, standard deviation.

*pvalue <0.05.

Table 2.

Demographic and clinical data

HyposecretorsNormosecretorsHypersecretorsp valueHyposecretorsNormosecretorsHypersecretorsp value
A+T+A+T−A+T+A+T−A+T+A+T−
Age, median (IQR), years 71 (9) 72 (6) 75 (10) 0.153 72 (6) 69 (12) 71 (7) 73 (7.5) 74 (7.75) 81 (0) 0.258 
Male sex, n (%) 7 (9.2) 20 (26.3) 1 (1.3) 0.315 3 (3.9) 4 (5.3) 19 (25) 1 (1.3) 0 (0) 1 (1.3) 0.176 
HT, n (%) 11 (14.5) 18 (23.7) 4 (5.3) 0.523 5 (6.6) 6 (7.9) 16 (21.1) 2 (2.6) 3 (3.9) 1 (1.3) 0.823 
DL, n (%) 15 (19.7) 25 (32.9) 2 (2.6) 0.175 8 (10.5) 7 (9.2) 22 (28.9) 3 (3.9) 2 (2.6) 0 (0) 0.552 
DM2, n (%) 5 (6.6) 10 (13.2) 0 (0) 0.500 2 (2.6) 3 (3.9) 9 (11.8) 1 (1.3) 0 (0) 0 (0) 0.868 
Family history of dementia, n (%) 11 (14.5) 15 (19.7) 3 (3.9) 0.321 7 (9.2) 4 (5.3) 14 (18.4) 1 (1.3) 3 (3.9) 0 (0) 0.410 
Initial MoCA score, mean (SD) 18.18 (6.352) 18.21(5.332) 18.14 (1.574) 0.999 17.64 (5.938) 18.73 (6.987) 18 (5.314) 20 (5.745) 18 (1,673) 19 (−) 0.974 
Initial GDS stage, median (IQR) 3 (1) 3 (0) 3 (1) 0.595 3 (1) 3 (0) 3 (0) 3 (1) 3 (1) 2 (0) 0.286 
HyposecretorsNormosecretorsHypersecretorsp valueHyposecretorsNormosecretorsHypersecretorsp value
A+T+A+T−A+T+A+T−A+T+A+T−
Age, median (IQR), years 71 (9) 72 (6) 75 (10) 0.153 72 (6) 69 (12) 71 (7) 73 (7.5) 74 (7.75) 81 (0) 0.258 
Male sex, n (%) 7 (9.2) 20 (26.3) 1 (1.3) 0.315 3 (3.9) 4 (5.3) 19 (25) 1 (1.3) 0 (0) 1 (1.3) 0.176 
HT, n (%) 11 (14.5) 18 (23.7) 4 (5.3) 0.523 5 (6.6) 6 (7.9) 16 (21.1) 2 (2.6) 3 (3.9) 1 (1.3) 0.823 
DL, n (%) 15 (19.7) 25 (32.9) 2 (2.6) 0.175 8 (10.5) 7 (9.2) 22 (28.9) 3 (3.9) 2 (2.6) 0 (0) 0.552 
DM2, n (%) 5 (6.6) 10 (13.2) 0 (0) 0.500 2 (2.6) 3 (3.9) 9 (11.8) 1 (1.3) 0 (0) 0 (0) 0.868 
Family history of dementia, n (%) 11 (14.5) 15 (19.7) 3 (3.9) 0.321 7 (9.2) 4 (5.3) 14 (18.4) 1 (1.3) 3 (3.9) 0 (0) 0.410 
Initial MoCA score, mean (SD) 18.18 (6.352) 18.21(5.332) 18.14 (1.574) 0.999 17.64 (5.938) 18.73 (6.987) 18 (5.314) 20 (5.745) 18 (1,673) 19 (−) 0.974 
Initial GDS stage, median (IQR) 3 (1) 3 (0) 3 (1) 0.595 3 (1) 3 (0) 3 (0) 3 (1) 3 (1) 2 (0) 0.286 

The subgroups were adequately comparable according to the distribution of the demographic data. No significant differences were found for the stage of presentation or initial neuropsychological evaluation.

DM2, type 2 diabetes mellitus; DL, dyslipidemia; GDS, Global Deterioration Scale; HT, hypertension; IQR, interquartile range; MoCA, Montreal Cognitive Assessment; n, number; q, quartile; SD, standard deviation.

Biomarker concentrations (pg/mL) were not significantly different between the amnestic and non-amnestic subgroups: Aβ40 10,140.500, interquartile range (IQR) = 7,409 versus 9,489, IQR = 4,024 (p = 0.682); Aβ42 377, IQR = 224 versus 385.500, IQR = 292 (p = 0.284); Aβ42/Aβ40 0.042, SD = 0.01 versus 0.046, SD = 0.01 (p = 0.063); p-Tau 111.842, SD = 70.72 versus 102.044, SD = 51.53 (p = 0.265); and total-Tau 695.230, SD = 391.02 versus 646.570, SD = 312.99 (p = 0.288). Amnestic syndrome was the most frequent IWG-2 phenotype, being found in 48 (63.2%) participants, followed by frontal variant in 21 (27.6%) participants. The distribution of AD phenotypes did not differ among subgroups both in the raw and in the stratified analyses nor did changes in the MoCA score (Table 3).

Table 3.

Phenotypical distribution and cognitive decline according to biomarker status

HyposecretorsNormosecretorsHypersecretorsp valueHyposecretorsNormosecretorsHypersecretorsp value
A+T+A+T−A+T+A+T−A+T+A+T−
Atypical AD variant, n (%) 7 (9.2) 19 (25) 2 (2.6) 0.703 4 (5.3) 3 (33.9) 14 (18.4) 5 (6.6) 2 (7.1) 0 (0) 0.069 
IWG-2 phenotype, n (%) 
Amnestic syndrome 15 (19.7) 28 (36.8) 5 (6.6) 0.738 7 (9.2) 8 (10.5) 28 (36.8) 0 (0) 4 (5.3) 1 (1.3) 0.151 
Posterior variant 0 (0) 3 (3.9) 0 (0) 0 (0) 0 (0) 3 (3.9) 0 (0) 0 (0) 0 (0) 
Logopenic variant 1 (1.3) 2 (2.6) 1 (1.3) 1 (1.3) 0 (0) 2 (2.6) 0 (0) 1 (1.3) 0 (0) 
Frontal variant 6 (7.9) 14 (18.4) 1 (1.3) 3 (3.9) 3 (3.9) 9 (11.8) 5 (6.6) 1 (1.3) 0 (0) 
ΔMoCA score, median (IQR) −1.82 (2.34) −1.19 (4.20) 0.82 (13.02) 0.190 −1.72 (6.33) −1.92 (2.76) −1.21 (3.96) 0.41 (0) 0 (11.70) 9.94 (0) 0.456 
Progression to dementia (GDS ≥4), median (IQR), years 0.76 (2) 0.86 (1.50) 1.08 (1.95) 0.953 0.55 (2.15) 1.30 (1.53) 0.85 (1.50) 0.86 (1.93) 1.05 (2.03) 1.08 (0) 0.945 
Progression to moderate dementia (GDS ≥5), mean (SD), years 1.53 (1.10) 1.61 (0.91) 1.71 (1.41) 0.916 1.44 (1.02) 1.62 (1.22) 1.61 (0.89) 1.63 (1.14) 1.81 (1.51) 1.08 (1.08) 0.978 
HyposecretorsNormosecretorsHypersecretorsp valueHyposecretorsNormosecretorsHypersecretorsp value
A+T+A+T−A+T+A+T−A+T+A+T−
Atypical AD variant, n (%) 7 (9.2) 19 (25) 2 (2.6) 0.703 4 (5.3) 3 (33.9) 14 (18.4) 5 (6.6) 2 (7.1) 0 (0) 0.069 
IWG-2 phenotype, n (%) 
Amnestic syndrome 15 (19.7) 28 (36.8) 5 (6.6) 0.738 7 (9.2) 8 (10.5) 28 (36.8) 0 (0) 4 (5.3) 1 (1.3) 0.151 
Posterior variant 0 (0) 3 (3.9) 0 (0) 0 (0) 0 (0) 3 (3.9) 0 (0) 0 (0) 0 (0) 
Logopenic variant 1 (1.3) 2 (2.6) 1 (1.3) 1 (1.3) 0 (0) 2 (2.6) 0 (0) 1 (1.3) 0 (0) 
Frontal variant 6 (7.9) 14 (18.4) 1 (1.3) 3 (3.9) 3 (3.9) 9 (11.8) 5 (6.6) 1 (1.3) 0 (0) 
ΔMoCA score, median (IQR) −1.82 (2.34) −1.19 (4.20) 0.82 (13.02) 0.190 −1.72 (6.33) −1.92 (2.76) −1.21 (3.96) 0.41 (0) 0 (11.70) 9.94 (0) 0.456 
Progression to dementia (GDS ≥4), median (IQR), years 0.76 (2) 0.86 (1.50) 1.08 (1.95) 0.953 0.55 (2.15) 1.30 (1.53) 0.85 (1.50) 0.86 (1.93) 1.05 (2.03) 1.08 (0) 0.945 
Progression to moderate dementia (GDS ≥5), mean (SD), years 1.53 (1.10) 1.61 (0.91) 1.71 (1.41) 0.916 1.44 (1.02) 1.62 (1.22) 1.61 (0.89) 1.63 (1.14) 1.81 (1.51) 1.08 (1.08) 0.978 

No significant differences were found for distinctive symptoms on presentation, the decrease in neuropsychological evaluation, or the dementia stage throughout the follow-up.

AD, Alzheimer’s disease; GDS, Global Deterioration Scale; IQR, interquartile range; IWG-2, International Working Group-2; MoCA, Montreal Cognitive Assessment; n, number; q, quartile; SD, standard deviation.

There were no significant differences among subgroups in the time of progression to dementia (Table 3; Fig. 2). No correlation was found between Aβ40 levels and changes in the MoCA score (ρ = 0.185, p = 0.141), Aβ40 and time of progression to mild dementia (ρ = 0.045, p = 0.700), or between that of biomarker and time of progression to moderate dementia (r = −0.003, p = 0.979).

Fig. 2.

Progression to the dementia stage according to biomarker status. The different subgroups showed similar progression rates to either mild or moderate dementia stages in the Kaplan-Meier analysis. GDS, Global Deterioration Scale.

Fig. 2.

Progression to the dementia stage according to biomarker status. The different subgroups showed similar progression rates to either mild or moderate dementia stages in the Kaplan-Meier analysis. GDS, Global Deterioration Scale.

Close modal

In the logistic regression analysis, collinearity was found for total Tau and p-Tau (variance inflation factor = 12.688 and 12.506, respectively), so the former was removed from the model. Aβ40, Aβ42, p-Tau, and age were included as predictors. No significant association was found between the presence of a non-amnestic phenotype and Aβ40 (p = 0.134), p-Tau (p = 0.175), or age (p = 0.051). Aβ42 levels were positively associated with presenting a non-amnestic AD variant (p = 0.036, OR = 1.007, 95% CI = 1.000–1.013). The model showed a significant fit (χ2 = 10.348, p = 0.035). Classification precision, specificity, and sensitivity were 72%, 89.6%, and 40.7%, respectively. Regarding progress to the mild dementia stage, no predictors showed significant associations: Aβ40 (p = 0.439), Aβ42 (p = 0.485), p-Tau (p = 0.387), or age (p = 0.632). No significant interactions were found for Aβ40 (p = 0.672), Aβ42 (p = 0.563), p-Tau (p = 0.744), or age (p = 0.839) and progress to moderate dementia.

In our study, the concentration of CSF Aβ40 in AD patients did not correlate with the initial symptoms of the disease, the intensity of the cognitive decline as measured by the MoCA test, or the progression to the dementia stage. CSF biomarkers for AD have played a critical role in paving the road toward standardizing a biological definition of the disease and have homogenized its diagnostic and research criteria [20, 22]. The value of CSF biomarkers as a diagnostic tool for neurodegenerative diseases has been further stated with their proven ability to differentiate among parkinsonian syndromes [23]. The additional measurement of Aβ40 has been demonstrated to reflect amyloid positron emission tomography status better than Aβ42 alone [12] and to provide clinicians with a more accurate AD diagnosis [13] as it normalizes Aβ42 concentration to total amyloid-β peptides. Studies on Aβ40 as an independent biomarker and its possible relationship with the clinical or pathological aspects of AD have been otherwise scarce. In an anatomopathological series, no significant difference was found in its concentration between patients with AD and subjects with other neurodegenerative dementias [24]. Very recently, Verde et al. [25] reported preliminary data regarding the role of Aβ40 and p-Tau levels in differentiating amnestic from atypical AD phenotypes [25], pointing toward possible slightly different biochemical and neuropathological changes underlying non-amnestic forms. However, our study did not replicate their results. We did observe a positive correlation between Aβ40 and p-Tau, and between Aβ40 and total-Tau, in concordance with previous observations [26], that reinforces the hypothesized modulation of Tau pathology by amyloid-β peptides. Although the exact link between these two pathological hallmarks remains to be elucidated, mouse models suggest that early accumulation of Aβ peptides induces a progressive conformation of Tau seeds into larger aggregates [27]. In prospective studies, CSF p-Tau and total-Tau have shown an increase in amyloid-positive individuals, with Aβ biomarkers somehow preceding Tau pathology but failing to show a steady rise themselves [11, 28]. This finding might suggest that higher levels of the former respond to disease progression and neuronal damage (Tau has proved to be a reliable indicator of disease progression and cognitive decline [29, 30]), though without a clinical correlation as measured by the tools employed in our study. Thus, amyloid pathology might be an initial and necessary step that subsequently drives disease progression in AD patients. However, as Aβ deposits precede by decades the emergence of symptoms [1], the latest stages of AD could become independent of amyloid pathology and be more related to unspecific mechanisms of neurodegeneration in which Tau pathology might play a leading role [31]. Further association with biomarkers for neurodegeneration such as neurofilament light protein [32], a set of data not available from our study population, would support this hypothesis. CSF Aβ40 levels reliably reflect total Aβ load [26] and therefore show interindividual variability, but if AD progresses and Tau pathology becomes the dominant process, it is unlikely that they serve such function in normalizing p-Tau levels even though they were mechanistically related.

CSF biomarkers have been widely considered of particular interest in the search for a better understanding of the elusive mechanisms underlying AD as its interaction with the extracellular space of the encephalon would plausibly reflect the neuropathological changes occurring [33]. However, research on the clinical correlation of amyloid-β peptides has not yielded remarkable results. The concentration of CSF Aβ42 has been inversely correlated with amyloid plaque load both in anatomopathological [5, 34] and amyloid-positron emission tomography imaging series [7, 35]. The remarkable stability of that peptide throughout the disease progression has prevented allocating Aβ42 a defined pathological role [11, 28]. Nonetheless, soluble Aβ oligomers appear to be the toxic form of amyloid instead of plaques themselves [36], a fact that might account for the absence of a clinical connotation of Aβ42 levels. In that sense, we found no apparent effect of Aβ40 in the progression of cognitive decline or the clinical presentation of the disease either. The finding of a considerable proportion of cognitively normal subjects showing Aβ deposition has contributed to the reframing of the role of amyloid in AD pathogenesis [37]. The high frequency of concomitant pathology according to recent anatomopathological data further indicates a considerably higher complexity of the mechanisms involved [38]. Regarding the potential role of Aβ42 as a predictor of a non-amnestic AD variant observed in our study, the OR value is not sufficient to be deemed clinically meaningful. Future studies should evaluate the predictive value of Aβ biomarkers for atypical variants as it was not the primary aim of our work.

Despite the retrospective design of our study and its subsequent limitations, the lack of a significant association between Aβ40 and the phenotype or course of the disease but with a positive correlation with p-Tau and total-Tau requires consideration. It suggests a prominent role of Aβ40 in neurodegeneration, though not a determinant of clinical manifestations or prognosis. An IWG-2 phenotype different from amnestic syndrome was reported for a third of the participants. Atypical variants of AD are estimated to represent around a third of the patients with an early onset of the disease, while they would only account for 6% of late-onset cases [39]. Although the measurement of CSF biomarkers has steadily become a standard diagnostic procedure for patients presenting to our Cognitive Disorders Clinic, the proportion of participants with non-amnestic AD phenotypes might be overrepresented in our sample as it is a helpful tool for an adequate distinction among the different neurodegenerative dementias in the case of an atypical presentation. Further studies with a prospective design are deemed to establish the role of Aβ40 within the neurodegenerative process and how its interindividual variability might influence other constituents of AD.

In the present study, no significant differences were found in the clinical manifestations or progression of the disease in AD patients according to their Aβ40 concentration. Aβ40 positively correlated with p-Tau and total Tau concentrations, supporting their probable interaction in AD pathophysiology.

This study protocol was reviewed and approved by the Ethics Committee at Hospital Universitario La Paz on April 28th, 2022; approval number PI-5239. The study obtained a waiver of informed consent from the Ethics Committee at Hospital Universitario La Paz.

The authors have no conflicts of interest to declare.

No funding was received.

J.G.C. contributed to study design, manuscript writing, and data acquisition. H.M.S. and O.R.F. contributed to laboratory analysis and manuscript revision. M.H.B. and S.S.L. contributed to data acquisition and manuscript revision. A.F.G. contributed to manuscript revision and critical reading. A.M.M. contributed to study design and manuscript revision.

All data generated or analyzed during this study are included in this article. Further inquiries can be directed to the corresponding author.

1.
Scheltens
P
,
de Strooper
B
,
Kivipelto
M
,
Holstege
H
,
Chételat
G
,
Teunissen
CE
.
Alzheimer’s disease
.
Lancet
.
2021 Apr 24
397
10284
1577
90
.
2.
Soria Lopez
JA
,
González
HM
,
Léger
GC
.
Alzheimer’s disease
. In:
Handbook of clinical neurology
Elsevier B.V.
2019
. p.
231
55
.
3.
Canter
RG
,
Penney
J
,
Tsai
LH
.
The road to restoring neural circuits for the treatment of Alzheimer’s disease
.
Nature
.
2016 Nov 9
539
7628
187
96
.
4.
Jack
C
,
Bennett
D
,
Blennow
K
,
Carrillo
M
,
Dunn
B
,
Haeberlein
S
.
NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease
.
Alzheimers Dement
.
2018 Apr 1
14
4
535
62
.
5.
Strozyk
D
,
Blennow
K
,
White
LR
,
Launer
LJ
.
CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study
.
Neurology
.
2003
;
60
(
4
):
652
6
.
6.
Molinuevo
JL
,
Ayton
S
,
Batrla
R
,
Bednar
MM
,
Bittner
T
,
Cummings
J
.
Current state of Alzheimer’s fluid biomarkers
.
Acta Neuropathol
.
2018
;
136
(
6
):
821
53
.
7.
Fagan
AM
,
Mintun
MA
,
Mach
RH
,
Lee
SY
,
Dence
CS
,
Shah
AR
.
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans
.
Ann Neurol
.
2006 Mar
59
3
512
9
.
8.
Li
G
,
Sokal
I
,
Quinn
JF
,
Leverenz
JB
,
Brodey
M
,
Schellenberg
GD
.
CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment A follow-up study
.
Neurology
.
2007
;
69
(
7
):
631
9
.
9.
Fagan
AM
,
Roe
CM
,
Xiong
C
,
Mintun
MA
,
Morris
JC
,
Holtzman
DM
.
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults
.
Arch Neurol
.
2007
;
64
(
3
):
343
9
.
10.
Blennow
K
,
Zetterberg
H
,
Minthon
L
,
Lannfelt
L
,
Strid
S
,
Annas
P
.
Longitudinal stability of CSF biomarkers in Alzheimer’s disease
.
Neurosci Lett
.
2007 May 23
419
1
18
22
.
11.
Toledo
JB
,
Xie
SX
,
Trojanowski
JQ
,
Shaw
LM
.
Longitudinal change in CSF Tau and Aβ biomarkers for up to 48 months in ADNI
.
Acta Neuropathol
.
2013 Nov
126
5
659
70
.
12.
Lewczuk
P
,
Matzen
A
,
Blennow
K
,
Parnetti
L
,
Molinuevo
JL
,
Eusebi
P
.
Cerebrospinal fluid aβ42/40 corresponds better than Aβ42 to amyloid PET in Alzheimer’s disease
.
J Alzheimers Dis
.
2017
;
55
(
2
):
813
22
.
13.
Dorey
A
,
Perret-Liaudet
A
,
Tholance
Y
,
Fourier
A
,
Quadrio
I
.
Cerebrospinal fluid Aβ40 improves the interpretation of Aβ42 concentration for diagnosing Alzheimer’s disease
.
Front Neurol
.
2015
;
6
:
247
.
14.
Hansson
O
,
Lehmann
S
,
Otto
M
,
Zetterberg
H
,
Lewczuk
P
.
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease
.
Alzheimers Res Ther
.
2019 Apr 22
11
1
34
15
.
15.
Reisberg
B
,
Ferris
S
,
de Leon
M
,
Crook
T
.
The global deterioration Scale for assessment of primary degenerative dementia
.
Am J Psychiatry
.
1982
;
139
(
9
):
1136
9
.
16.
Nasreddine
Z
,
Phillips
N
,
Bédirian
V
,
Charbonneau
S
,
Whitehead
V
,
Collin
I
.
The montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment
.
J Am Geriatr Soc
.
2005
;
53
(
4
):
695
9
.
17.
Folstein
M
,
Folstein
S
,
Mchugh
P
.
“Mini-mental state” a practical method for grading the cognitive state of patients for the clinician
.
J Psychiatr Res
.
1975
;
12
(
3
):
189
98
.
18.
Gobom
J
,
Parnetti
L
,
Rosa-Neto
P
,
Vyhnalek
M
,
Gauthier
S
,
Cataldi
S
.
Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid
.
Clin Chem Lab Med
.
2022 Jan 1
60
2
207
19
.
19.
Leitão
MJ
,
Silva-Spínola
A
,
Santana
I
,
Olmedo
V
,
Nadal
A
,
le Bastard
N
.
Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer’s disease
.
Alzheimers Res Ther
.
2019 Nov 23
11
1
91
.
20.
Dubois
B
,
Feldman
HH
,
Jacova
C
,
Hampel
H
,
Molinuevo
L
,
Blennow
K
.
Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria
.
Lancet Neurol
.
2014
;
13
(
6
):
614
29
.
21.
Roheger
M
,
Xu
H
,
Hoang
MT
,
Eriksdotter
M
,
Garcia-Ptacek
S
.
Conversion between the mini-mental state examination and the montreal cognitive assessment for patients with different forms of dementia
.
J Am Med Dir Assoc
.
2022 Dec
23
12
1986
9.e1
.
22.
Carrillo
M
,
Yong
KXX
,
Apostolova
LG
,
Bouwman
FH
,
Graff-Radford
J
,
Dickerson
BC
.
New insights into atypical Alzheimer’s disease in the era of biomarkers
.
Lancet Neurol
.
2021
;
20
(
3
):
222
34
.
23.
Kaiserova
M
,
Chudackova
M
,
Prikrylova Vranova
H
,
Mensikova
K
,
Kastelikova
A
,
Stejskal
D
.
Cerebrospinal fluid levels of 5-hydroxyindoleacetic acid in Parkinson’s disease and atypical parkinsonian syndromes
.
Neurodegener Dis
.
2021 Dec 1
21
1–2
30
5
.
24.
Slaets
S
,
le Bastard
N
,
Martin
JJ
,
Sleegers
K
,
van Broeckhoven
C
,
de Deyn
PP
.
Cerebrospinal fluid Aβ1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels
.
J Alzheimers Dis
.
2013
;
36
(
4
):
759
67
.
25.
Verde
F
,
Aiello
E
,
Giacopuzzi Grigoli
E
,
Milone
I
,
Dubini
A
,
Ratti
A
.
CSF Aβ40 and P-tau181 might differentiate atypical from typical AD phenotypes: preliminary evidence
.
Neurodegener Dis
.
2022
;
22
(
2
):
83
6
.
26.
Wiltfang
J
,
Esselmann
H
,
Bibl
M
,
Hüll
M
,
Hampel
H
,
Kessler
H
.
Amyloid β peptide ratio 42/40 but not Aβ42 correlates with phospho-Tau in patients with low- and high-CSF Aβ40 load
.
J Neurochem
.
2007 May
101
4
1053
9
.
27.
He
Z
,
Guo
JL
,
McBride
JD
,
Narasimhan
S
,
Kim
H
,
Changolkar
L
.
Amyloid-β plaques enhance Alzheimer’s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation
.
Nat Med
.
2018 Jan 1
24
1
29
38
.
28.
Milà-Alomà
M
,
Salvadó
G
,
Gispert
JD
,
Vilor-Tejedor
N
,
Grau-Rivera
O
,
Sala-Vila
A
.
Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer’s continuum
.
Alzheimers Dement
.
2020 Oct 1
16
10
1358
71
.
29.
Pascoal
TA
,
Mathotaarachchi
S
,
Shin
M
,
Benedet
AL
,
Mohades
S
,
Wang
S
.
Synergistic interaction between amyloid and tau predicts the progression to dementia
.
Alzheimers Dement
.
2017 Jun 1
13
6
644
53
.
30.
Degerman Gunnarsson
M
,
Ingelsson
M
,
Blennow
K
,
Basun
H
,
Lannfelt
L
,
Kilander
L
.
High tau levels in cerebrospinal fluid predict nursing home placement and rapid progression in Alzheimer’s disease
.
Alzheimers Res Ther
.
2016 Jun 6
8
1
22
.
31.
Jack
C
,
Knopman
DS
,
Jagust
WJ
,
Shaw
LM
,
Aisen
PS
,
Weiner
MW
.
Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade
.
Lancet Neurol
.
2010
;
9
(
1
):
119
28
.
32.
Petzold
A
,
Keir
G
,
Warren
J
,
Fox
N
,
Rossor
MN
.
A systematic review and meta-analysis of CSF neurofilament protein levels as biomarkers in dementia
.
Neurodegener Dis
.
2007 Jun
4
2–3
185
94
.
33.
Blennow
K
,
Dubois
B
,
Fagan
AM
,
Lewczuk
P
,
de Leon
MJ
,
Hampel
H
.
Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer’s disease
.
Alzheimers Dement
.
2015
;
11
(
1
):
58
69
.
34.
Tapiola
T
,
Alafuzoff
I
,
Herukka
SK
,
Parkkinen
L
,
Hartikainen
P
,
Soininen
H
.
Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain
.
Arch Neurol
.
2009
;
66
(
3
):
382
9
.
35.
Grimmer
T
,
Riemenschneider
M
,
Förstl
H
,
Henriksen
G
,
Klunk
WE
,
Mathis
CA
.
Beta amyloid in Alzheimer’s disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid
.
Biol Psychiatry
.
2009 Jun 1
65
11
927
34
.
36.
Sengupta
U
,
Nilson
AN
,
Kayed
R
.
The role of amyloid-β oligomers in toxicity, propagation, and immunotherapy
.
EBioMedicine
.
2016 Apr 1
6
42
9
.
37.
Rowe
CC
,
Bourgeat
P
,
Ellis
KA
,
Brown
B
,
Lim
YY
,
Mulligan
R
.
Predicting Alzheimer disease with β-amyloid imaging: results from the Australian imaging, biomarkers, and lifestyle study of ageing
.
Ann Neurol
.
2013 Dec
74
6
905
13
.
38.
Robinson
J
,
Lee
E
,
Xie
S
,
Rennert
L
,
Suh
E
,
Bredenberg
C
.
Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated
.
Brain
.
2018 Jul 1
141
7
2181
93
.
39.
Koedam
ELGE
,
Lauffer
V
,
van der Vlies
AE
,
van der Flier
WM
,
Scheltens
P
,
Pijnenburg
YAL
.
Early-versus late-onset Alzheimer’s disease: more than age alone
.
J Alzheimers Dis
.
2010
;
19
(
4
):
1401
8
.